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Abstract 
Introduction: Increased incidence of obesity and excess weight leads to an increased 
incidence of nonalcoholic fatty liver disease (NAFLD). Recent evidence indicates a 
protective effect of cannabis consumption on weight gain and related metabolic 
alterations in psychosis patients. Overall, patients are at greater risk of presenting fatty 
diseases, such as NAFLD, partly due to lipid and glycemic metabolic disturbances. 
However, there are no previous studies on the likely effect of cannabis on liver steatosis. 
We aimed to explore if cannabis consumption had an effect on hepatic steatosis, in a 
sample of first-episode (FEP) non-affective psychosis.  
Material and Methods: A total of 390 patients were evaluated at baseline and after 3 
years of initiating the antipsychotic treatment. Anthropometric measurements and liver, 
lipid, and glycemic parameters were obtained at both time points. All but 6.7% of 
















points. Liver steatosis and fibrosis were evaluated through validated clinical scores 
(Fatty Liver Index [FLI], Fibrosis-4 [FIB-4], and NAFLD). 
Results: At 3-year follow-up, cannabis users presented significantly lower FLI scores 
than nonusers (F = 13.874; p < 0.001). Moreover, cannabis users less frequently met the 
criteria for liver steatosis than non-users (X2 = 7.97, p = 0.019). Longitudinally, patients 
maintaining cannabis consumption after 3 years presented the smallest increment in FLI 
overtime, which was significantly smaller than the increment in FLI presented by 
discontinuers (p = 0.022) and never-users (p = 0.016). No differences were seen in 
fibrosis scores associated with cannabis. 
Conclusions: Cannabis consumption may produce a protective effect against liver 




 Cannabis consumption is associated with a lower risk of liver steatosis in 
psychosis. 
 Cannabis use is not associated with liver fibrosis. 
 The cannabis effect on liver tissue might be through the modulation of weight 
gain. 
 A direct effect of cannabis on liver tissue has not been ruled out.  
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Patients with psychosis who are treated with antipsychotic medication are at greater risk 
of presenting altered liver function tests (Baeza et al., 2018), even from the early stages 
of psychosis (Erdogan et al., 2008), and an increased risk of chronic liver disease in the 
long term (Hsu et al., 2014). Although the mechanisms underlying the relation between 
antipsychotics and liver damage are not fully understood, previous studies demonstrated 
that treated schizophrenic patients (Gilles et al., 2010; Joseph et al., 2011; Konarzewska 
et al., 2014) exhibited an increased visceral and liver fat distribution compared with 
controls. In a recent study, we showed a significant incidence of nonalcoholic fatty liver 
disease (NAFLD) in a sample of patients with first-episode psychosis in the first 3 years 
of antipsychotic treatment (Morlán-Coarasa et al., 2016); in the same direction, a recent 
study reported a greater prevalence of NAFLD in patients with chronic schizophrenia 
(Yan et al., 2017). NAFLD, a condition of liver damage consisting of excessive 
accumulation of lipids in the hepatic tissue, has been associated with sedentary lifestyle 
and excess caloric diet (Romero-Gómez et al., 2017), among other factors leading to  
obesity and lipid/glycemic metabolic alterations (Targher, 2007). And these risk factors 
and metabolic disorders are  frequently present  in patients with psychosis (Vázquez-
Bourgon et al., 2018). Interestingly, cannabis use, which is highly prevalent among 
psychotic patients (Green et al., 2005; Pelayo-Terán et al., 2008; Setien-Suero et al., 
2017), has recently been associated with a protective effect against weight gain and 
obesity in psychosis (Vázquez-Bourgon et al., 2019 ; Scheffler et al., 2018). 
However, to our knowledge, there are no previous studies exploring the possible effect 
of cannabis consumption on liver steatosis in psychosis. 
Based on the evidence described above, we hypothesized that those patients with a first 
episode of non-affective psychosis who also use cannabis will present less frequently 
with NAFLD than psychotic patients who are non-users, suggesting a protective effect 
of cannabis on the liver. 
The aim of this study was to explore, longitudinally, whether cannabis consumption has 
an effect on hepatic steatosis in a sample of patients with first-episode non-affective 
psychosis after 3 years of antipsychotic treatment. 
 
2. Materials and methods 
















The sample population for the present study was recruited between 2001 and 2015 and 
formed part of a larger prospective longitudinal study on first-episode non-affective 
psychosis (Pelayo-Teran et al., 2008). Patients aged between 16 and 60 years who 
presented a first episode of non-affective psychosis with a confirmation diagnosis (at 6-
month follow-up; Diagnostic and Statistical Manual of Mental Disorders, fourth edition 
[DSM-IV] criteria) of schizophrenia, schizophreniform disorder, schizoaffective 
disorder, brief reactive psychosis, or psychosis not otherwise specified were included in 
the program. Patients were not admitted to the program if they presented any of the 
following: (1) intellectual disability, (2) neurological disorder, or (3) drug dependence 
(DSM-IV criteria). All subjects provided written informed consent prior to their 
inclusion in the study. The study was approved by the local ethics committee 




Patients attended clinical appointments with the same experienced psychiatrist on a 
regular basis and at least at baseline, 3 weeks, 6 weeks, 3 months, 6 months, and every 6 
months thereafter until year 3. Patients were treated and maintained on antipsychotic 
treatment during the follow-up period. Certain concomitant medications were permitted 
if clinically needed, including lormetazepam and clonazepam (benzodiazepine receptor 
agonists, nonselective GABA-A receptor-positive allosteric modulators) for the 
management of agitation, general behavior disturbances, and/or insomnia; 
anticholinergic medication (biperiden at a dose of up to 8 mg/day) when clinically 
significant extrapyramidal signs occurred; or antidepressants (sertraline, a serotonin 
transporter reuptake inhibitor) and mood stabilizers (lithium, enzyme interactions). 
Cannabis consumption (past-year cannabis use) as well as alcohol and tobacco (yes or 
no) were assessed based on patients’ self-reported information. Alcohol consumption 
was also recorded as a continuous variable in units and grams of alcohol per week. No 
distinction was made between the route of cannabis administration (smoking or 
ingestion), the part of the plant used, or potency. Information on daily quantity was 
collected, but as we were unable to quantify these data reliably, this was not included in 
the analyses. 
The patients’ weight and waist circumference were determined at baseline and at 3-year 
















body mass index (BMI) was computed as their body weight (kg) divided by height in 
square meters. 
 
2.2.2. Laboratory analyses 
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), Gamma-
glutamyltransferase (GGT), alkaline phosphatase, bilirubin, serum albumin, and 
triglycerides, platelets count, leptin, and high-sensitivity C-reactive protein were 
determined from peripheral blood samples. All determinations were performed in our 
hospital. All measurements were obtained at the first visit and at the 3-year follow-up, 
after an overnight fast. Triglycerides were measured by an automated method on a 
TechniconDax (Technicon Instruments Corp, Tarrytown, NY, USA) using reagents 
supplied by Boehringer-Mannheim (Mannheim, Germany). 
 
2.2.3. Liver steatosis and fibrosis assessments 
The Fatty Liver Index (FLI) (Bedogni et al. 2006) was determined at baseline and 3 
years. The FLI consists of an algorithm that predicts fatty liver disease based on BMI, 
waist circumference, and triglyceride and gammaglutamyl transferase levels, with an 
accuracy of 0.84 (95% confidence interval, 0.81–0.87). The FLI varies from 0 to 100. A 
score lower than 30 rules out fatty liver disease (negative likelihood ratio = 0.2), and a 
score greater than or equal to 60 suggests fatty liver disease (positive likelihood ratio = 
4.3). 
Liver fibrosis was evaluated also through validated clinical scores; the NAFLD fibrosis 
and Fibrosis-4 (FIB-4) scores (Angulo et al. 2007; Sterling et al. 2006). The NAFLD 
fibrosis score consists of an algorithm that predicts fibrosis based on age, BMI, the 
presence of diabetes and/or insulin resistance, the AST:ALT ratio, the platelet count, 
and albumin levels. A score ≤1.455 rules out liver fibrosis with a negative predictive 
value of 93%, whereas a score ≥0.676 predicts liver fibrosis with a positive predictive 
value of 90%. The FIB-4 score is another algorithm based on age, platelet count, and 
AST and ALT levels. A score ≤1.30 rules out liver fibrosis with a negative predictive 
value of 90%, whereas a score ≥2.67 predicts liver fibrosis with a positive predictive 
value of 80%. 
 
2.3. Statistical analysis 
















We conducted separate cross-sectional analysis of covariance (ANCOVA) models for 
exploring the possible effect of cannabis use on liver health at baseline and at 3 years. 
For this purpose, the liver disease indexes (FLI, FIB-4, and NAFLD) and the liver and 
laboratory parameters listed above were the dependent variables, and cannabis 
consumption status (yes/no) was the independent variable. Age, sex, smoking status 
(yes/no), and alcohol intake (yes/no), were entered in the model as covariables to avoid 
their potential effect as confounding factors. Post hoc correction (Bonferroni) was 
applied. 
 
2.3.2. Longitudinal examinations 
To examine the longitudinal effects of cannabis, we divided patients into three 
trajectory consumption groups: “continuers” (cannabis users at baseline who continued 
smoking at the 3-year assessment), “discontinuers” (patients using cannabis upon 
entering the program but who did not at the 3-year follow-up), and “never-users” 
(patients who reported not using cannabis at either time point). A forth category 
(“cannabis starters”) was not considered since only three patients (0.8% of the total 
sample) started consuming cannabis during the 3 years follow-up; these three patents 
were excluded from the study to enable the statistical comparisons between groups.  
General lineal model (GLM) repeated-measures tests were conducted for each 
dependent variable of liver functioning separately (e.g.: FLI, FIB-4, or AST), with 
cannabis consumption groups  (“continuers”, “discontinuers”, and “never-users”) as the 
between-subject variable and time (baseline, 3-year follow-up) as within-subject 
variable. Effects of time (longitudinal dimension), and time by cannabis consumption 
group (interaction effect) were examined. Sex and age at baseline, and alcohol and 
tobacco longitudinal consumption groups were included as covariates. All post-hoc 
comparisons were Bonferroni corrected. 
We additionally calculated the percentage of subjects with pathologic values for FLI  
and the main liver parameters, at baseline and at the 3-year follow-up, in each cannabis-
consuming group (continuers, discontinuers, never-users). To evaluate significant 
changes over time in these percentages within groups, we used the McNemar test for 
repeated measures.  
 
















Alcohol dependence was an exclusion criterion for entering the study. However, to 
maximize the avoidance of the effect of alcohol use on liver steatosis, we repeated the 
statistical analyses after excluding those patients with moderate-severe alcohol 
consumption at any of the time points. Moderate-severe alcohol use was defined using 
the accepted alcohol consumption thresholds for the diagnosis of NAFLD: 140 and 210 
grams of alcohol per week in women and men, respectively (Leoni et al., 2018).  
  
The Statistical Package for Social Science (SPSS) version 22.0 (IBM, Armonk, NY, 
USA) was used for the statistical analyses. All statistical tests were two-tailed, and the 




3.1. Sample characteristics 
A total of 390 patients with data of cannabis consumption at both time points were 
included in this study. The sample had a mean age of 30.4 years, 44.4% (n = 173) were 
women, and 81.8% (n = 319) were diagnosed with schizophrenia or schizophreniform 
disorder. The mean duration of untreated psychosis was 12.8 months (SD = 29.7), and 
the mean Scale for the Assessment of Positive Symptoms–Scale for the Assessment of 
Negative Symptoms score was 20.3 (SD = 7.7). At baseline, 38.5% (n = 150) were 
cannabis users. All but 6.7% (n = 26) of patients included in the study were drug-naïve. 
Among those that were not drug-naïve, their mean duration of previous antipsychotic 
exposure was 1.6 weeks (SD = 1.5). In any case, those non-drug-naïve patients were not 
significantly (all p > 0.1) different from the drug-naïve group in any of the main 
variables studied at baseline. A more detailed description of the clinical and socio-
demographic characteristics of the study sample, including the differences between 
cannabis consumption groups at baseline, is available in Vázquez-Bourgon et al., 
(submitted). 
 
3.2. Baseline and 3-year liver differences between cannabis users and nonusers 
When comparing cross-sectionally cannabis users and nonusers (Table 1), the 
ANCOVA models showed a significant association only with leptin at both time points. 
Thus, cannabis users presented significant lower leptin levels before and 3 years after 
















laboratory parameters studied were significantly associated with cannabis consumption 
at baseline or 3 years. However, the results also showed a significantly lower mean FLI 
among cannabis users at 3-year follow-up compared with nonusers (11.8 vs 40.3; F = 
13.784, p < 0.001). Subsequent, X2 tests showed that cannabis users at 3-year follow-up 
presented less frequently an FLI score equal to or greater than 60 than nonusers (11.1% 
vs. 28.3%; X2 = 7.97, p = 0.019). This association remained significant after Yates’s 
correction (X2 = 6.01, p = 0.049). 
 
3.3. Comparison of longitudinal changes in liver steatosis between cannabis 
users, nonusers, and discontinuers. 
We found a significant interaction between cannabis consumption trajectories (users, 
discontinuers, and never-users) and time in FLI score (F = 4.42; p = 0.014) (Table 2). 
Additionally, we found a trend-level interaction between cannabis consumption 
trajectories and time in BMI (F=2.72; p=0.067). Post-hoc analyses revealed that patients 
who maintained the cannabis consumption (n=14) did not presented significant changes 
in FLI scores (p=0.892; estimated mean difference = 0.9), over a 3-year period. On the 
other hand, patients that abandoned the cannabis consumption (n=40) and those that 
never smoked cannabis (n=104) exhibited significant increments in FLI scores over the 
3-year follow-up period (both p <0.001; estimated mean differences = 20.8 and 21.7, 
respectively). 
 
3.4. Incidence of high levels of liver parameters and indexes over 3 years of 
antipsychotic treatment and cannabis use.  
McNemar tests (Table 3) showed significant increments in the percentage of patients 
with liver parameters above the normal limits (ALT >40, GGT >32; %difference = 6, p 
= 0.021; and %difference = 11.4, p < 0.001, respectively). Unexpectedly, with regard to 
AST, the significant association was in the inverse direction; there was a significant 
reduction over time in the proportion of patients scoring above the upper-normal limit 
(AST >35; %difference = –6.3, p = 0.013).  
When analyzing other laboratory tests, we also observed significant increments in the 
percentage of patients scoring above the upper-normal limit for leptin and high-
sensitivity C-reactive protein (%difference = 25.1, p < 0.001; and %difference = 14.6, p 
















Finally, regarding the FLI score, we observed a significant increment in the percentage 
of patients with a score suggestive of liver steatosis (FLI >60; %difference = 18.9, p < 
0.001). 
Only one patient presented an FIB-4 score suggestive of liver fibrosis (FIB-4 score = 
3.00). None of the patients presented an FIB-4 score greater than 2.67 at 3-year follow-
up. Similarly, no patients presented a high NAFLD fibrosis score at any time point. 
Therefore, we were unable to analyze the association between liver fibrosis and 
cannabis consumption in our sample. 
When comparing the changes in the proportion of patients with values above the normal 
limits, in each of the cannabis-consuming trajectories (users, discontinuers, and never-
users; Table 3), we observed that, for most of the parameters, the group of cannabis 
consumers presented smaller increments than the discontinuers and never-users.  
 
3.5. Post hoc analyses.  
Thirty (7.7%) patients at baseline and 20 (5.1%) at 3-year follow-up reported elevated 
alcohol consumption (>210 g per week in men and >140 g per week in women). The 
results from statistical analyses, after excluding these patients (n = 40), remained the 
same; for a detailed description of these results see Tables 2-4 in Vázquez-Bourgon et 
al. (submitted). In the same direction, when FLI was analyzed as a qualitative variable, 
the significant association between cannabis use and FLI remained significant, where 
cannabis users presented less frequently an FLI ≥60 than nonusers (6.7% vs. 26.1%; X2 
= 9.89, p = 0.007) after 3 years of antipsychotic treatment. This association remained 
significant after Yates’s correction (X2 = 7.46, p = 0.024). 
 
4. Discussion 
We present the first study exploring the effect of cannabis consumption on liver health 
in a sample of patients with a first episode of psychosis. The results showed that those 
patients who reported continuing cannabis use were at lower risk of developing NAFLD 
in the first 3 years after the illness onset.  
Cannabis consumers presented significantly lower mean FLI scores than non-users at 
the 3-year follow-up. This association was also seen using FLI as a qualitative measure 
of steatosis; thus, among cannabis users, there were significantly fewer patients meeting 
the criteria for NAFLD than among non-users after 3 years of antipsychotic treatment. 
















patients discontinuing cannabis consumption during the 3-year follow-up period 
presented a similar increase in mean FLI as never-users, with the increments in mean 
FLI in these two groups significantly greater than the increment observed in the 
continuers group.  
These differences between groups in mean scores of FLI had clinical relevance, since 
there were important differences in the percentage of patients reaching a FLI score 
predictive of steatosis after 3 years of treatment: 7% of consumers versus 30% and 27% 
of  discontinuers and never-users, respectively.  
These results are in line with previous studies in the general population (Adejumo et al., 
2017), in which cannabis users showed significantly lower NAFLD prevalence 
compared with non-users. This association between cannabis consumption and lower 
NAFLD prevalence has also been identified in subgroups of patients with other 
pathologies. For instance, cannabis consumption among patients with abusive alcohol 
use significantly reduced the odds of developing alcoholic steatosis, steatohepatitis, 
fibrosis, cirrhosis, and hepatocellular carcinoma (Adejumo et al., 2018). In the same 
direction, those patients co-infected by the human immunodeficiency and hepatitis C 
viruses, and reporting the use of cannabis, showed a a reduced risk of steatosis 
(Nordmann et al., 2018), and did not accelerate the progression of liver disease (Brunet 
et al., 2013). Similarly, cannabis use was associated with a decreased incidence of liver 
cirrhosis among hepatitis C virus patients (Adejumo et al., 2018b). However, some 
studies showed contrary evidence. Using imaging techniques in a small sample of 30 
patients of chronic cannabis smokers, Muniyappa and colleagues (2013) found no 
association between cannabis and hepatic steatosis. In addition, daily cannabis use was 
associated with steatosis (Hezode et al., 2008) and liver fibrosis (Ishida et al., 2008) in 
patients with chronic hepatitis C disease.  
Regarding fibrosis, our results found no significant differences when analyzing the 
fibrosis scores (FIB-4 and NAFLD fibrosis) between groups, which may be explained 
by the young mean age of the sample and the insufficient follow-up (3 years) for the 
development of liver fibrosis. 
 
Cannabis users presented significantly lower levels of leptin compared with non-users, 
before and 3 years after initiating antipsychotic treatment. In addition, the proportion of 
patients with a leptin level above the upper normal limit significantly increased, after 
















cannabis users group. These results are  in line with recent data on cannabis use in the 
general population (Moreira et al., 2018) where cannabis smokers presented 
significantly lower levels of leptin than nonsmokers, in a population-based study. 
Leptin, a hormone that is mainly produced by the   adipocytes, and acting  on the 
hypothalamus, exerts a crucial role in energy balance and food intake. Leptin levels 
have been described to be elevated in schizophrenia patients (Kim et al., 2017; Pérez-
Iglesias et al., 2008) and in those exposed to antipsychotic treatment (Ragguett et al., 
2017). However, it has been proposed that the increase of leptin levels in these 
antipsychotic-exposed populations, is a consequence of augmented fat mass rather than 
being  induced directly by antipsychotic treatment (Perez-Iglesias et al., 2008). It 
appears that at increasing concentrations, leptin induces target cells to become resistant 
to its own action (Lustig et al., 2004), leading to a “leptin-resistance” state in which 
leptin loses its satiating effect at the central level. Therefore, impaired leptin signaling 
does not seem to be the primary mechanism implicated in weight gain induced by 
antipsychotics;  subsequently, the differences in leptin levels observed in our results, 
associated with cannabis use, appear to be secondary to the effect of cannabis on weight 
(Vázquez-Bourgon et al,. 2019; Scheffler et al., 2018). This would explain the 
contradictory data in the literature regarding the effect of cannabis on the liver, with a 
previous study reporting a profibrogenic effect of cannabis (Ishida et al., 2008). 
 
The effects of cannabis use on weight and lipid/glycemic metabolism may be explained 
by its  interaction with the endocannainoid system (ECS). The ECS includes two main 
receptors, cannabinoid type 1 and 2 receptors (CB1R and CB2R), whose major ligands 
are endogenous cannabinoids. These receptors are found in the central nervous system 
and various peripheral tissues, including the liver (Pertwee, 2008; Gong et al., 2006; 
Galiègue et al., 1995; Spigelman, 2010) playing a possible role in its functionality. 
Under healthy conditions, cannabinoid receptors are weakly expressed in the liver;  
CB1R in hepatocytes and endothelial cells, and CB2R in Kupffer cells. However, 
hepatic damage is associated with an increase in the expression of both receptors 
(Mallat & Lotersztajn, 2008). Thus, it is likely that cannabis plays a role in liver disease. 
CB1R seems to promote liver damage (Hsiao et al., 2015; Osei-Hyiaman et al., 2005; 
Osei-Hyiaman et al., 2008), while CB2R might have a protective effect (Di Marzo 
2008; Mallat et al., 2007; Kunos et al., 2006). Thus, cannabis may promote a beneficial 
















note that Δ9-tetrahydrocannabivarin  and cannabidiol, two of the main cannabis 
components, were able to increase lipid mobilization and inhibit the development of 
hepatosteatosis, in in vitro and in vivo (animal models) experiments (Silvestri et al., 
2015). In line with this, we observed a lower mean FLI among cannabis users compared 
with non-users. Thus, further studies testing the role of cannabinoids and cannabinoid 
receptors could help to elucidate the mechanisms involved in  the possible protective 
role of cannabis on liver damage (Begg et al., 2005).  
On the other hand, Kim and colleagues (2017) also showed a protective role of 
marijuana against body weight gain, attributed to a lower fasting insulin level. Liver 
diseases are often associated with insulin resistance and occur when the liver 
accumulates too much fat, altering the metabolism of glucose. Interestingly,  
rimonabant, a CB1R antagonist, improved insulin sensitivity in an experimental model 
(Ganesh & Rustgi, 2016), and similarly, cannabidiol can act as a CB1R antagonist, 
providing the possible link of insulin in our results (Thomas et al., 2007; Tam et al., 
2011). In addition, cannabis users tend to consume higher calories and alcohol than 
nonusers and nonetheless seem to have a lower prevalence of body weight gain. 
Therefore, cannabis could protect the liver, even in the face of the dietary risks that 
cannabis users often show. This possible protective effect could be exerted through an 
intermediate beneficial effect on lipid and glycemic metabolism; in fact, previous 
studies (Bruins et al., 2016; Vázquez-Bourgon et al., 2019) showed that the 
discontinuation of cannabis use increased the metabolic risk.  
 
Strengths and limitations 
This study has several relevant limitations. First, the data regarding cannabis use were 
self-reported, and no confirmation by toxicological urinalysis was performed, which 
may have introduced information bias. However, information and self-reports given by 
subjects tend to be relatively accurate (Buchan et al., 2002; Harrison et al., 1993). 
Notably, the patients who were enrolled in our program went through a process in 
which both clinical and behavioral data were collected from both themselves and their 
relatives. We thus feel confident as to the utility of the self-reported measurements of 
substance use in our sample. Despite of this, we acknowledge that the study lacks some 
relevant information regarding cannabis use; frequency, amount, and lifetime duration 
of cannabis use. No distinction was made about the parts of the plant used or the 
















with diverse effects and action mechanisms, at both cannabinoid and non-cannabinoid 
receptors (Elsohly & Slade, 2005; Hill et al., 2012). Therefore, further studies in animal 
models would be helpful to determine the mechanisms underlying the possible 
protective role of cannabis in NAFLD.  
Second, the mean age of the sample (30.4 years) hinders the occurrence of liver 
steatosis, since it is a pathological process that requires a longer period of time to 
develop.  
Third, the definition and diagnosis of NAFLD through the FLI score may be too 
weighted by BMI, and it is possible that we are just observing a proxy of a protective 
effect of cannabis on BMI changes, as we have previously described in the same sample 
(Vázquez-Bourgon et al., 2019).  However, the FLI score and fibrosis scores (NAFLD 
and FIB-4) are considered to be validated, noninvasive tools for the screening and 
diagnosis of liver damage (Leoni et al., 2018). Despite this, our results should be further 
explored and confirmed using imaging techniques, liver stiffness, and/or liver biopsy. 
Fourth, the impact of diet and physical activity on our findings herein cannot be ruled 
out, since a thorough description of these variables in our sample during follow-up was 
not available. In addition, concomitant medication may potentially interfere with the 
endocannabinoid system and might play a significant role in our findings. It is 
remarkable that chronic antidepressant treatment (serotonin and norepinephrine 
reuptake inhibitors and serotonin reuptake inhibitors) produces changes in cannabinoid 
receptors, modifying their expression (Smaga et al., 2017). 
Despite these limitations, the study has several strengths. First, it is to our knowledge 
the first study to explore the possible impact of cannabis on liver steatosis in a sample 
of patients with psychosis. Second, its design as a pragmatic clinical trial facilitates the 
generalization of the results to other clinical populations. Third, using a well-
characterized sample of drug-naïve patients recently diagnosed with a first episode of 
non-affective psychosis helps to avoid the confounding effect of chronicity and long-
term exposure to medications. Fourth, the long-term follow-up period (3 years) 
facilitates the detection of early liver alterations such as steatosis. 
 
Conclusions 
Our results suggest that using cannabis could have a protective effect on liver steatosis. 
















secondary to its modulation effect on weight gain and the reduced development of 
obesity, although a direct effect of cannabis on the hepatic tissue has not been ruled out.  
These results, although obtained from a sample of patients with psychosis, could be 
generalized; the hepatic alterations that may occur associated with the rapid increase in 
weight produced in our sample may be seen as an appropriate pragmatic experimental 
model for the study of steatosis.   
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Table 1.  Baseline and 3-years liver function tests in first episode psychosis. 
 Baseli
ne  
    3-
years 











































































































































* ANCOVA model: parameter was used as the dependent variable, cannabis use was the 
fixed factor and age, sex, and tobacco and alcohol consumption use were used as 
covariates. 
Abbreviations: FLI, fatty liver Index; BMI, body mass index; GGT,  Gamma-
glutamyltransferase ; AST, aspartate aminotransferase ; ALT, alanine aminotransferase;  
AP, alkaline phosphatase; hsCRP, high sensitivity C-reactive protein; FIB-4, fibrosis 4 
score; NAFLD, non-alcoholic fatty liver disease fibrosis score. 
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* GLM repeated-measure model.  
Abbreviations: FLI, fatty liver Index; BMI, body mass index; GGT,  Gamma-
glutamyltransferase ; AST, aspartate aminotransferase ; ALT, alanine aminotransferase;  
AP, alkaline phosphatase; hsCRP, high sensitivity C-reactive protein; FIB-4, fibrosis 4 
score; NAFLD, non-alcoholic fatty liver disease fibrosis score. 
 
Table 3. Comparison of proportion of subjects with pathological liver functions tests, at 
baseline and at 3-years in each cannabis consumption group. 
 Baseline 3 year follow-
up 
   
 % (n) % (n) % difference N p* 
AST, >35  UI/L      
Continuer 23.7 (9) 13.2 (5) -10.5 38 0.344 
Discontinuers 13.3 (12) 8.9 (8) -4.4 90 0.454 
Non-users 15.0 (33) 8.6 (19) -8.4 220 0.054 
Total 15.5 (54) 9.2 (32) -6.3 348 0.013 
ALT, >40 UI/L      
Continuer 17.5 (7) 22.5 (9) 5 40 0.727 
Discontinuers 9.0 (9) 20.0 (20) 11 100 0.027 
Non-users 13.9 (32) 17.7 (41) 3.8 231 0.281 
Total 12.9 (48) 18.9 (70) 6 371 0.021 
GGT, >32 UI/L      
Continuer 2.6 (1) 20.5 (8) 17.9 39 0.016 
Discontinuers 7.6 (7) 20.7 (19) 13.1 92 0.004 
Non-users 11.8 (26) 21.4 (47) 11.6 220 0.001 
Total 9.7 (34) 21.1 (74) 11.4 351 <0.001 
Leptin, >10 ng/ml      
Continuer 3.8 (1) 11.5 (3) 7.7 26 0.500 
















Non-users 36.5 (66) 64.1 (116) 27.6 181 <0.001 
Total 27.0 (76) 52.1 (147) 25.1 282 <0.001 
hsCRP, >0.3 ng/dL      
Continuer 11.1 (1) 0 (0) -11.1 9 - 
Discontinuers 6.7 (3) 22.2 (10) 15.1 45 0.039 
Non-users 7.7 (8) 24.0 (25) 16.3 104 0.002 
Total 7.6 (12) 22.2 (35) 14.6 158 <0.001 
FLI ≥60      
Continuer 0 (0) 7.1 (1) 7.1 14 - 
Discontinuers 5.0 (2) 30.0 (12) 25 40 0.002 
Non-users 8.7 (9) 26.9 (28) 18.2 104 <0.001 
Total 7.0  (11) 25.9 (41) 18.9 158 <0.001 
*McNemar test for repeated measures.  
Abbreviations: FLI, fatty liver Index; GGT,  Gamma-glutamyltransferase ; AST, aspartate 
aminotransferase ; ALT, alanine aminotransferase;  hsCRP, high sensitivity C-reactive protein. 
 
Highlights 
 Cannabis consumption is associated with a lower risk of liver steatosis in psychosis. 
 Cannabis use is not associated with liver fibrosis. 
 The cannabis effect on liver tissue might be through the modulation of weight gain. 
 A direct effect of cannabis on liver tissue has not been ruled out.  
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